WO2023148662A9 - Sapropterin formulation - Google Patents

Sapropterin formulation Download PDF

Info

Publication number
WO2023148662A9
WO2023148662A9 PCT/IB2023/050932 IB2023050932W WO2023148662A9 WO 2023148662 A9 WO2023148662 A9 WO 2023148662A9 IB 2023050932 W IB2023050932 W IB 2023050932W WO 2023148662 A9 WO2023148662 A9 WO 2023148662A9
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
sapropterin
present disclosure
contemplated
dispersed
Prior art date
Application number
PCT/IB2023/050932
Other languages
French (fr)
Other versions
WO2023148662A1 (en
Inventor
Chris Wagstaff
Steve TICKLE
Original Assignee
Apr Applied Pharma Research S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apr Applied Pharma Research S.A. filed Critical Apr Applied Pharma Research S.A.
Priority to CA3241169A priority Critical patent/CA3241169A1/en
Priority to AU2023215745A priority patent/AU2023215745A1/en
Publication of WO2023148662A1 publication Critical patent/WO2023148662A1/en
Publication of WO2023148662A9 publication Critical patent/WO2023148662A9/en
Priority to CONC2024/0011386A priority patent/CO2024011386A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The present disclosure relates to a formulation of sapropterin. The formulation comprises a solid suspension of sapropterin dispersed within an oil. Methods of treatment using the formulation are also contemplated by the present disclosure.
PCT/IB2023/050932 2022-02-02 2023-02-02 Sapropterin formulation WO2023148662A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA3241169A CA3241169A1 (en) 2022-02-02 2023-02-02 Sapropterin formulation
AU2023215745A AU2023215745A1 (en) 2022-02-02 2023-02-02 Sapropterin formulation
CONC2024/0011386A CO2024011386A2 (en) 2022-02-02 2024-08-23 Sapropterin formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2201356.9 2022-02-02
GBGB2201356.9A GB202201356D0 (en) 2022-02-02 2022-02-02 Sapropterin formulation

Publications (2)

Publication Number Publication Date
WO2023148662A1 WO2023148662A1 (en) 2023-08-10
WO2023148662A9 true WO2023148662A9 (en) 2023-10-19

Family

ID=80621220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/050932 WO2023148662A1 (en) 2022-02-02 2023-02-02 Sapropterin formulation

Country Status (6)

Country Link
US (1) US20230241069A1 (en)
AU (1) AU2023215745A1 (en)
CA (1) CA3241169A1 (en)
CO (1) CO2024011386A2 (en)
GB (1) GB202201356D0 (en)
WO (1) WO2023148662A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828685C (en) * 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
TR201914406A2 (en) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT

Also Published As

Publication number Publication date
GB202201356D0 (en) 2022-03-16
WO2023148662A1 (en) 2023-08-10
CA3241169A1 (en) 2023-08-10
AU2023215745A1 (en) 2024-06-20
US20230241069A1 (en) 2023-08-03
CO2024011386A2 (en) 2024-09-09

Similar Documents

Publication Publication Date Title
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
WO2019023635A8 (en) Substituted-3h-imidazo(4,5-c)pyridine and 1h-pyrrolo(2,3-c)pyridine series of novel ectonucleotide pyrophsphatase/phosphodiestrase-1 (enpp1) and stimulator for interferon genes (sting) modulator as cancer immunotherapeutics
WO2004098494A3 (en) Compounds, compositions, and methods
MX2007000044A (en) Tetrahydroquinazolin-4(3h)-one-related and tetrahydropyrido[2,3-d ]pyrimidin-4(3h)-one-related compounds, compositions and methods for their use.
JOP20210285A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
AU2660484A (en) 4-phenylamino pyrimidines
MX2022003166A (en) Il-17a modulators and uses thereof.
CR20210513A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2004037342A3 (en) Electrical stimulation of the brain
MX2023011065A (en) Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors.
WO2022115944A8 (en) Carboxylated psilocybin derivatives and methods of using
WO2020214031A9 (en) Vehicle comprising a chassis assembly and method of adjusting the length thereof
WO2023148662A9 (en) Sapropterin formulation
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2021118276A3 (en) Sulfur-producing microorganism and method for producing sulfur by using same
WO2021178976A3 (en) Prenyltransferases and methods of making and use thereof
MX2023010590A (en) NEW 2,3-DIHYDRO-1H-PYRROLO[3,2-b]PYRIDINE DERIVATIVES AS SIGMA LIGANDS.
WO2022200105A8 (en) Compounds as soluble epoxide hydrolase inhibitors
WO2019193561A3 (en) Insect-repellent composition comprising one or more insect-repellent fatty acids having between 9 and 21 carbon atoms
EP3984533A3 (en) Compositions comprising choline and their use
WO2024039901A3 (en) Cdk2 degraders and uses thereof
WO2022216900A3 (en) Synthesis of rapamycin analog compounds
WO2023010065A3 (en) Compositions and methods for anti-pacap antibodies
WO2021022111A3 (en) β-ARRESTIN-MODULATING COMPOUNDS AND METHODS OF USING SAME
WO2022011338A3 (en) Kinase modulators and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23703651

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023215745

Country of ref document: AU

Ref document number: AU2023215745

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3241169

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023215745

Country of ref document: AU

Date of ref document: 20230202

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024013607

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2023703651

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023703651

Country of ref document: EP

Effective date: 20240902